全文获取类型
收费全文 | 2234篇 |
免费 | 163篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 124篇 |
妇产科学 | 15篇 |
基础医学 | 181篇 |
口腔科学 | 51篇 |
临床医学 | 264篇 |
内科学 | 606篇 |
皮肤病学 | 29篇 |
神经病学 | 141篇 |
特种医学 | 269篇 |
外科学 | 137篇 |
综合类 | 31篇 |
预防医学 | 180篇 |
眼科学 | 127篇 |
药学 | 64篇 |
中国医学 | 7篇 |
肿瘤学 | 173篇 |
出版年
2023年 | 27篇 |
2022年 | 10篇 |
2021年 | 29篇 |
2020年 | 17篇 |
2019年 | 32篇 |
2018年 | 55篇 |
2017年 | 25篇 |
2016年 | 38篇 |
2015年 | 38篇 |
2014年 | 49篇 |
2013年 | 54篇 |
2012年 | 67篇 |
2011年 | 61篇 |
2010年 | 55篇 |
2009年 | 77篇 |
2008年 | 76篇 |
2007年 | 68篇 |
2006年 | 61篇 |
2005年 | 60篇 |
2004年 | 64篇 |
2003年 | 62篇 |
2002年 | 63篇 |
2001年 | 57篇 |
2000年 | 57篇 |
1999年 | 48篇 |
1998年 | 54篇 |
1997年 | 60篇 |
1996年 | 69篇 |
1995年 | 56篇 |
1994年 | 49篇 |
1993年 | 57篇 |
1992年 | 46篇 |
1991年 | 81篇 |
1990年 | 59篇 |
1989年 | 81篇 |
1988年 | 63篇 |
1987年 | 67篇 |
1986年 | 76篇 |
1985年 | 71篇 |
1984年 | 51篇 |
1983年 | 23篇 |
1982年 | 32篇 |
1981年 | 18篇 |
1980年 | 14篇 |
1979年 | 14篇 |
1978年 | 10篇 |
1977年 | 20篇 |
1976年 | 21篇 |
1975年 | 17篇 |
1971年 | 9篇 |
排序方式: 共有2408条查询结果,搜索用时 0 毫秒
71.
To determine the efficacy of converting-enzyme inhibition in patients with low-renin congestive heart failure (CHF), the long-term hemodynamic and clinical responses to captopril were evaluated in 26 consecutive patients with severe, chronic CHF whose pretreatment plasma renin activity (PRA) was less than 2 ng/ml/hour. After 2 to 8 weeks of continuous treatment with captopril, 14 patients (54%) showed long-term hemodynamic benefits, of whom 13 (50%) improved clinically by at least 1 New York Heart Association functional class. To distinguish responders from nonresponders, patients were grouped based on the presence or absence of sustained reactive hyperreninemia (PRA during chronic therapy greater than 4 ng/ml/hour). After 2 to 8 weeks of therapy with captopril, 14 patients had sustained reactive hyperreninemia. Their cardiac index increased by 0.33 liters/min/m2 (p less than 0.01), left ventricular filling pressure decreased by 12.6 mm Hg (p less than 0.001), mean right atrial pressure decreased by 4.9 mm Hg (p less than 0.001) and systemic vascular resistance decreased by 529 dyne s cm-5 (p less than 0.001). Twelve of these 14 patients improved clinically. Twelve other patients had no reactive increase in PRA, and these patients showed no significant improvement in any hemodynamic variable after 2 to 8 weeks of treatment with captopril; only 1 of the 12 patients improved clinically (p less than 0.001 between groups). The 2 groups were otherwise similar with regard to pretreatment demographic, hemodynamic and hormonal variables.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
72.
van Gils FC; van Teeffelen ME; Neelis KJ; Hendrikx J; Burger H; van Leen RW; Knol E; Wagemaker G; Wognum AW 《Blood》1995,86(2):592-597
To understand the hematopoietic and nonhematopoietic responses to interleukin-3 (IL-3), expression of cell-surface IL-3 receptors (IL-3R) was examined on bone marrow (BM) cells and peripheral blood (PB) cells of rhesus monkeys during the course of in vivo IL-3 treatment. Whereas IL-3R expression is low in untreated monkeys, IL-3 administration led to a gradual increase in both low- and high-affinity binding sites for IL-3. This increase reflected the total number of cells expressing IL- 3Rs, as detected by flow cytometry using biotinylated IL-3. Most of these IL-3R+ cells in both BM and PB could be characterized as basophilic granulocytes that contained high levels of histamine. In contrast to the effect on these differentiated cells, IL-3 administration did not significantly alter the low level IL-3R expression on immature, CD34+ cells. Further flow cytometric analysis using biotinylated growth factors showed that the IL-3R+ basophils also expressed receptors for granulocyte-macrophage colony-stimulating factor (GM-CSF), but not for IL-6 or Kit ligand. These findings indicated that the IL-3R+ cells included neither monocytes, which express GM-CSFRs and IL-6Rs abundantly, nor mast cells, which express c- kit. By combining flow cytometric and Scatchard data, it was calculated that the basophils contain as many as 1 to 2 x 10(3) high-affinity IL- 3Rs and 15 to 30 x 10(3) low-affinity sites. The finding that in vivo IL-3 treatment leads to the production of large numbers of cells that express high levels of IL-3R and are capable of producing histamine provides an explanation for the often severe allergic reactions that occur during prolonged IL-3 administration. It also indicates that IL- 3, in addition to its direct effects on hematopoietic cells, may also stimulate hematopoiesis through the release of secondary mediators such as histamine by IL-3-responsive mature cells. 相似文献
73.
Moe GW Rouleau JL Charbonneau L Proulx G Arnold JM Hall C de Champlain J Barr A Sirois P Packer M 《American heart journal》2000,139(4):587-595
BACKGROUND: Flosequinan is a direct-acting vasodilator that exerts beneficial hemodynamic effects and improves the exercise tolerance of patients with heart failure. However, a multicenter trial has demonstrated that long-term administration of flosequinan is associated with increased mortality rate. To explore a possible role of neurohormonal activation on this adverse outcome, we conducted a substudy to examine the plasma levels of 3 neurohormonal systems known to have prognostic implications in heart failure. METHODS: At 20 participating Canadian centers, paired plasma samples at baseline and 1 month after randomization for the measurement of N-terminal atrial natriuretic peptide (N-ANP), angiotensin II, and norepinephrine were obtained in 234 patients (114 receiving flosequinan and 120 receiving placebo). RESULTS: Treatment with flosequinan was associated with a decline in median plasma N-ANP levels (2139 pmol/L at baseline to 1625 pmol/L at 1 month [P =. 0001]), unchanged plasma angiotensin II levels (40 to 50 pmol/L [P =. 2700]), and a modest increase in plasma norepinephrine levels (391 to 439 pg/mL [P =.002]). These changes were not observed in the placebo group. Multivariate analysis of baseline variables revealed that plasma norepinephrine level predicted patients' death whereas analysis incorporating both baseline and 1-month variables indicated that plasma N-ANP level predicted patients' death. Furthermore, in the flosequinan group, a significant decline in plasma N-ANP level was observed in the survivors only. On multivariate analysis of baseline and 1-month data, the increase in plasma norepinephrine level did not predict the increase in heart rate associated with the use of flosequinan, suggesting that the 2 effects might be mediated by separate mechanisms. CONCLUSIONS: Results of our study demonstrate that in patients with severe heart failure, baseline norepinephrine level predicts death. Flosequinan increases plasma norepinephrine level and heart rate in these patients through mechanisms that override its beneficial hemodynamic effects. Our study reinforces the concept that the direct actions of a pharmacologic agent may have a more profound impact on the prognosis of these patients than the hemodynamic effects. 相似文献
74.
Milton Packer William T Abraham Mandeep R Mehra Clyde W Yancy Christine E Lawless Judith E Mitchell Frank W Smart Rachel Bijou Christopher M O'Connor Barry M Massie Ileana L Pina Barry H Greenberg James B Young Daniel P Fishbein Paul J Hauptman Robert C Bourge John E Strobeck Srinvivas Murali Douglas Schocken John R Teerlink Wayne C Levy Robin J Trupp Marc A Silver 《Journal of the American College of Cardiology》2006,47(11):2245-2252
OBJECTIVES: This study sought to assess the potential utility of impedance cardiography (ICG) in predicting clinical deterioration in ambulatory patients with heart failure (HF). BACKGROUND: Impedance cardiography uses changes in thoracic electrical impedance to estimate hemodynamic variables, but its ability to predict clinical events has not been evaluated. METHODS: We prospectively evaluated 212 stable patients with HF and a recent episode of clinical decompensation who underwent serial clinical evaluation and blinded ICG testing every 2 weeks for 26 weeks and were followed up for the occurrence of death or worsening HF requiring hospitalization or emergent care. RESULTS: During the study, 59 patients experienced 104 episodes of decompensated HF (16 deaths, 78 hospitalizations, and 10 emergency visits). Multivariate analysis identified 6 clinical and ICG variables that independently predicted an event within 14 days of assessment. These included three clinical variables (visual analog score, New York Heart Association functional class, and systolic blood pressure) and three ICG parameters (velocity index, thoracic fluid content index, and left ventricular ejection time). The three ICG parameters combined into a composite score was a powerful predictor of an event during the next 14 days (p = 0.0002). Visits with a high-risk composite score had 2.5 times greater likelihood and those with a low-risk score had a 70% lower likelihood of a near-term event compared with visits at intermediate risk. CONCLUSIONS: These results suggest that when performed at regular intervals in stable patients with HF with a recent episode of clinical decompensation, ICG can identify patients at increased near-term risk of recurrent decompensation. 相似文献
75.
76.
77.
Holly M. Burke Monique P. Mueller Catherine Packer Brian Perry Leonard Bufumbo Daouda Mbengue Bocar Mamadou Daff Anthony Mbonye 《Contraception》2014
Background
Sayana® Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in Uniject™, has potential to be a valuable innovation in family planning (FP) because it may overcome logistic and safety challenges in delivering intramuscular DMPA (DMPA IM). However, SP's acceptability is unknown. We measured acceptability of SP among clinic-based providers (Senegal only) and community health workers.Study design
This open-label observational study was conducted in clinics in three districts in Senegal and community-based services in two districts in Uganda. Providers administered SP to clients seeking reinjection of DMPA IM. We conducted in-depth interviews with 86 providers (52 in Senegal, 34 in Uganda) to assess their experiences providing SP to clients.Results
Almost all providers (84/86; 98%) preferred SP over DMPA IM. The main reason Uganda providers preferred SP was the prefilled/all-in-one design made preparation and administration easier and faster. Some providers thought the SP all-in-one feature may decrease stock outs (DMPA IM requires syringe and vial). Providers also felt clients preferred the shorter SP needle because it is less intimidating and less painful. Similarly, the main reasons Senegal providers preferred SP were its characteristics (prefilled/all-in-one) and client preference (especially less pain). They also saw a potential to increase access to FP, especially through community-based distribution. Providers from both countries reported SP introduction would be enhanced through client counseling and community engagement. Providers also said SP must be accessible, affordable and in stock.Conclusion
Almost all providers preferred SP over DMPA IM. Provider recommendations should be considered during SP introduction planning.Implications
We found that SP was acceptable to both clinic-based FP providers and community health workers. Providers' positive attitudes towards SP may facilitate introduction and uptake of this method. 相似文献78.
79.
80.